No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Zhejiang Jolly Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, manufacturing, and global distribution of traditional Chinese medicinal products. The company's diverse portfolio includes the Wuling capsule, prescribed for conditions such as insomnia, amnesia, heart palpitations, general fatigue, weakness in the lower back and legs, and tinnitus. This capsule also addresses energy deficiency and a weak pulse often linked to an imbalance of the heart and kidneys, or neurasthenia. Additionally, they produce the Lingze tablet, which targets frequent or painful urination, weak or continuous urine flow, and lower back and knee soreness, especially when these symptoms are associated with benign prostatic hyperplasia, kidney insufficiency, or blood stasis. Another offering, the Bailing tablet, serves as an adjunctive treatment for coughs, asthma, back pain, and chronic bronchitis stemming from lung and kidney deficiencies. The firm also markets Linglianhua particles, used to manage symptoms including excessive sweating, sleep disturbances, irritability, heart flutters, vivid dreams, dizziness with tinnitus, lower back and leg weakness, dry stools, an unusual tongue appearance, and a feeble pulse, often seen in perimenopausal syndrome or heart and kidney disharmony. Beyond these traditional Chinese medicine formulations, Zhejiang Jolly Pharmaceutical provides a range of injectable pharmaceuticals, such as azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside. The company further supplies raw medicinal ingredients, including cordyceps cephalosporium, fermented cordyceps, and Wuling powders. Expanding its reach into healthcare services, Zhejiang Jolly Pharmaceutical Co., Ltd. invests in and participates with Deqing No.3 People's Hospital. Established in 2000 and based in Huzhou, China, the entity now known as Zhejiang Jolly Pharmaceutical Co., Ltd. adopted this name in 1998, evolving from its earlier designation, Zhejiang Jolly Pharmaceutical Health Products Co., LTD.
www.zuoli.comNo one on the platform currently holds 300181.SZ.
No tracked institution reports a position in 300181.SZ as of their last filing.
No one on the platform has traded 300181.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 20.4% | 17.8% | 10.4% | — | — | — |
| Rev. Growth % | 18.0% | 22.8% | ||||
| Profit Margin % | 20.8% | 17.5% | 11.7% | |||
| Free Cash Flow Margin % | 4.1% | 5.7% | 2.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.7B | +24.9% | $1.04 | $1.04–$1.04 | — | 1 |
| 2027 | $4.4B | +17.8% | $1.26 | $1.26–$1.26 | — | 1 |
| 2028 | $5.0B | +14.7% | $1.50 | $1.50–$1.50 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300181.SZZhejiang Jolly Pharmaceutical Co.,LTD | $13.19 | +0.23% | $9.1B | — |
| 002287.SZTibet Cheezheng Tibetan Medicine Co., Ltd. | $19.19 | +0.47% | $11.0B | — |
| 300294.SZChina Resources Boya Bio-pharmaceutical Group Co., Ltd. | $13.98 | +0.29% | $7.0B | — |
| 301207.SZHualan Biological Bacterin Inc. | $18.14 | +1.34% | $10.8B | — |
| 600201.SSJinyu Bio-technology Co., Ltd. |
| $11.65 |
| -0.34% |
| $12.9B |
| — |
| 600572.SSZhejiang CONBA Pharmaceutical Co.,Ltd. | $4.22 | -0.24% | $10.7B | — |
| 600645.SSVcanbio Cell & Gene Engineering Corp., Ltd | $17.83 | +0.00% | $8.1B | — |
Source: Financial Modeling Prep · peers by sector/industry